Shotlee LogoShotlee
Blog
Download on theApp Store
Get it onGoogle Play
Skip to main content
ROOT Brands® Fills GLP-1 Gap with CRUSH™ & SCULPT™ After Ozempic® & Wegovy® - Featured image
Metabolic Health

ROOT Brands® Fills GLP-1 Gap with CRUSH™ & SCULPT™ After Ozempic® & Wegovy®

Shotlee Editorial Team
Written by Shotlee Editorial TeamHealth Research & Writing
·April 8, 2026·5 min read

On this page

  • Understanding the GLP-1 Gap: Challenges After Ozempic® and Wegovy®
  • The CRUSH™ and SCULPT™ Protocol: A Cellular-First Solution
  • Who Benefits from CRUSH™ and SCULPT™?
  • Safety and Practical Guidance for Integration
  • About ROOT Brands®
  • Key Takeaways: Bridging the GLP-1 Gap
  • Conclusion: Sustainable Wellness Beyond Injections
  • Why the GLP-1 Gap Matters for Metabolic Health
  • CRUSH™: Supporting Metabolic Function and Energy
  • SCULPT™: Plant-Based Muscle and Composition Support

Track Smart

Calculate active GLP-1 levels automatically with Shotlee.

Download →

As millions using GLP-1 medications like Ozempic® and Wegovy® face post-treatment challenges such as muscle loss and weight regain, ROOT Brands® introduces CRUSH™ and SCULPT™. This cellular-first protocol supports metabolic function and lean muscle preservation without pharmaceuticals. Backed by science, it targets the 'GLP-1 gap' for long-term body composition success.

Share

On this page

  • Understanding the GLP-1 Gap: Challenges After Ozempic® and Wegovy®
  • The CRUSH™ and SCULPT™ Protocol: A Cellular-First Solution
  • Who Benefits from CRUSH™ and SCULPT™?
  • Safety and Practical Guidance for Integration
  • About ROOT Brands®
  • Key Takeaways: Bridging the GLP-1 Gap
  • Conclusion: Sustainable Wellness Beyond Injections
  • Why the GLP-1 Gap Matters for Metabolic Health
  • CRUSH™: Supporting Metabolic Function and Energy
  • SCULPT™: Plant-Based Muscle and Composition Support

GLP-1 receptor agonists like Ozempic® and Wegovy® have transformed weight management, but a growing concern known as the "GLP-1 gap" highlights unmet needs in metabolic and muscle support. ROOT Brands®, led by Chief Science Officer Dr. Christina Rahm and CEO Clayton Thomas, positions CRUSH™ and SCULPT™ as a targeted, non-pharmaceutical protocol to bridge this gap. Designed for users during and after GLP-1 therapy, these products promote cellular health, lean muscle preservation, and sustained metabolic efficiency.

Understanding the GLP-1 Gap: Challenges After Ozempic® and Wegovy®

GLP-1 medications such as Ozempic® and Wegovy® excel at suppressing appetite, slowing gastric emptying, and regulating blood sugar, facilitating significant short-term weight loss. However, they were not formulated to address key aspects of long-term success, including preservation of lean muscle mass, enhancement of cellular energy production, or support for metabolic adaptability.

Clinical observations and consumer reports reveal a common pattern post-discontinuation: appetite rebounds rapidly, resting metabolic rate declines, lean body mass diminishes, and weight regain often follows swiftly. Digestive discomfort and low energy levels further complicate the transition. This "GLP-1 gap" underscores the need for nutritional strategies that operate at the cellular level to sustain results.

Why the GLP-1 Gap Matters for Metabolic Health

Maintaining lean muscle is crucial because it drives resting metabolic rate—muscle tissue burns more calories at rest than fat. GLP-1 drugs primarily target fat loss through caloric restriction but can inadvertently contribute to muscle catabolism without countermeasures. Addressing this gap supports not just weight maintenance but overall vitality, energy levels, and resilience against regain.

For patients, recognizing these limitations empowers proactive planning. Those on Ozempic® or Wegovy® should monitor body composition metrics like muscle mass via DEXA scans or bioimpedance scales, and consider integrating supportive nutrition early to mitigate risks.

The CRUSH™ and SCULPT™ Protocol: A Cellular-First Solution

ROOT Brands® developed CRUSH™ and SCULPT™ to provide clean, non-pharmaceutical support aligned with their "cellular-first" philosophy: Clean the cell. Feed the cell. Protect the cell. This approach emphasizes efficient nutrient utilization, mitochondrial function, and cellular health to complement GLP-1 therapy.

CRUSH™: Supporting Metabolic Function and Energy

CRUSH™ features seven essential amino acids in a stimulant-free formula. These building blocks of protein aid healthy metabolic function, cellular energy processes, and natural fat utilization. Essential amino acids are vital during caloric deficits from GLP-1 use, helping prevent muscle breakdown and supporting recovery for daily energy without crashes or dependency.

Patients transitioning off injections benefit from CRUSH™'s role in restoring metabolic efficiency, countering the dip in resting metabolic rate often seen post-GLP-1.

SCULPT™: Plant-Based Muscle and Composition Support

SCULPT™ incorporates clinically studied ingredients like InnoSlim®, Gymnema Sylvestre, White Kidney Bean extract, and Valerian Root. This plant-based formula targets lean muscle support, body composition balance, strength preservation, and metabolic resilience.

Precision tracking for your journey

Join thousands using Shotlee to accurately track GLP-1 medications and side effects.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store
Get it onGoogle Play
  • InnoSlim®: Activates cellular pathways for glucose uptake and fat metabolism.
  • Gymnema Sylvestre: Traditionally used to modulate sugar absorption.
  • White Kidney Bean extract: Inhibits carb breakdown to aid composition goals.
  • Valerian Root: Promotes relaxation and recovery.

Together, CRUSH™ and SCULPT™ form a protocol ideal for GLP-1 users seeking sustained outcomes.

Who Benefits from CRUSH™ and SCULPT™?

This protocol suits:

  • Individuals currently using GLP-1 medications who want to support lean muscle and metabolic health.
  • Those transitioning off GLP-1 medications seeking a non-pharmaceutical nutritional approach.
  • People pursuing long-term body composition and metabolic support without injectable therapies.

Consult a healthcare provider before starting, especially if managing conditions like diabetes or gastrointestinal issues. Track progress with tools like symptom journals or apps such as Shotlee for monitoring energy, digestion, and side effects during transitions.

"GLP-1 medications can start the journey, but they were never intended to complete it," said Dr. Christina Rahm, Chief Science Officer of ROOT Brands®. "Long-term results require metabolic, muscular, and cellular support that goes beyond appetite suppression. CRUSH and SCULPT were created to help meet those needs."
"Search trends and consumer behavior make it clear-people recognize that something is missing after GLP-1," said Clayton Thomas, CEO of ROOT Brands®. "CRUSH and SCULPT were developed to support that moment and provide a structured, science-driven answer."

Safety and Practical Guidance for Integration

As non-drug supplements, CRUSH™ and SCULPT™ emphasize clean ingredients and transparent sourcing, minimizing interactions. Common GLP-1 side effects like nausea or fatigue may persist post-use; these products support digestive comfort and energy without stimulants.

Integration Tips:

  • Start during GLP-1 use to build muscle buffers.
  • Continue 4-8 weeks post-discontinuation for metabolic rebound prevention.
  • Pair with resistance training and protein-rich meals for synergy.
  • Monitor via regular check-ins with practitioners.

Compared to alternatives like isolated protein powders, this protocol's cellular focus and synergistic ingredients offer targeted GLP-1 gap coverage.

About ROOT Brands®

Based in Franklin, Tennessee, ROOT Brands® commits to science-driven, cellular-first nutrition. Under Dr. Christina Rahm and Clayton Thomas, products like CRUSH™, SCULPT™, Clean Slate™, Zero-In™, and Restore™ are distributed globally via independent partners, grounded in ingredient research.

Key Takeaways: Bridging the GLP-1 Gap

  • GLP-1 drugs like Ozempic® and Wegovy® drive weight loss but leave metabolic and muscle gaps.
  • CRUSH™ and SCULPT™ provide amino acid and plant-based support for cellular health and composition.
  • Ideal for during, after, or instead of GLP-1 therapy.
  • Emphasize doctor discussions and lifestyle integration for best results.

Conclusion: Sustainable Wellness Beyond Injections

The GLP-1 gap represents a pivotal opportunity for nutritional innovation. ROOT Brands® CRUSH™ and SCULPT™ empower users to sustain Ozempic® and Wegovy® gains through science-backed, cellular support. By addressing muscle preservation and metabolic resilience, this protocol fosters long-term body composition success—discuss with your provider to see if it's right for your journey.

?Frequently Asked Questions

What is the GLP-1 gap?

The GLP-1 gap refers to unmet needs in metabolic efficiency, lean muscle preservation, and cellular health after using medications like Ozempic® and Wegovy®, including risks of weight regain and low energy.

How do CRUSH™ and SCULPT™ support after GLP-1 medications?

CRUSH™ provides seven essential amino acids for metabolic function and energy, while SCULPT™ uses InnoSlim®, Gymnema Sylvestre, and other ingredients for muscle support and body composition during and post-GLP-1 use.

Who should use the CRUSH™ and SCULPT™ protocol?

It's designed for GLP-1 users maintaining muscle and metabolism, those transitioning off injections, or anyone seeking long-term body composition without pharmaceuticals—consult a doctor first.

What is ROOT Brands' cellular-first philosophy?

It follows 'Clean the cell. Feed the cell. Protect the cell.' to enhance nutrient utilization, mitochondrial function, and cellular health for sustainable wellness.

Are CRUSH™ and SCULPT™ safe with Ozempic® or Wegovy®?

As clean, non-pharmaceutical supplements, they complement GLP-1 therapy without stimulants; always discuss with a healthcare provider to ensure suitability.

Source Information

Originally published by The Manila times.Read the original article →

Read next

Keep exploring

More on Ozempic

Articles covering Ozempic dosing, side effects, and clinical updates.

What's the Deal with Peptides? The Hyped Market Under FDA Review
Health & Wellness

What's the Deal with Peptides? The Hyped Market Under FDA Review

An in-depth look at the FDA's review of unregulated peptide therapy, the safety concerns raised by experts, and the conflict between industry demand and clinical evidence.

8 min read
Eli Lilly, Novo Nordisk Address Awareness Gap for Medicare’s $50 GLP-1 Program
Health & Wellness

Eli Lilly, Novo Nordisk Address Awareness Gap for Medicare’s $50 GLP-1 Program

Learn how the new Medicare GLP-1 Bridge program works, which drugs are covered, and why major pharmaceutical companies are leading the awareness push for the $50 copay initiative.

8 min read
Eli Lilly's Retatrutide Shows Cardiovascular and Diabetic Benefits in Trials
Medical Research

Eli Lilly's Retatrutide Shows Cardiovascular and Diabetic Benefits in Trials

Eli Lilly's investigational drug, retatrutide, has shown promising results in clinical trials, offering substantial weight loss and significant improvements in cardiovascular health and type 2 diabetes management.

7 min read

Same topic: GLP-1 Medications

All GLP-1 Medications articles →
How Iconic Philly Food Brands Are Adapting to Calorie-Conscious Consumers
Health & Wellness

How Iconic Philly Food Brands Are Adapting to Calorie-Conscious Consumers

Philadelphia's iconic food brands are evolving, introducing high-protein and functional food options to cater to the growing number of calorie-conscious consumers, influenced by trends like GLP-1 medications and a desire for healthier choices.

8 min read
Doctors Warn a New GLP-1 Finding May Raise Your Risk of Smell Loss
Health

Doctors Warn a New GLP-1 Finding May Raise Your Risk of Smell Loss

Researchers analyzed nearly 877,000 patients and found a significant link between GLP-1 receptor agonists and sensory disturbances.

8 min read
I Lost 5 Stone on Mounjaro — But Now I’ve Had Enough
Health & Wellness

I Lost 5 Stone on Mounjaro — But Now I’ve Had Enough

Natalie Lavergne transformed her health and lost 5 stone using Mounjaro, but now plans to switch to the Wegovy pill. Discover the medical realities of stopping weight loss medication.

8 min read

More in Metabolic Health

Ozempic and GLP-1 Drugs: Heart Benefits and Personal Realities
Metabolic Health

Ozempic and GLP-1 Drugs: Heart Benefits and Personal Realities

Thirty million Americans—one in eight—are turning to GLP-1 drugs like Ozempic for weight management and more, with data showing a 20% reduced risk of heart attacks and strokes. But what happens when the weight doesn't budge, as in 10% of users? This personal story explores the hype, realities, and broader implications of these medications.

4 min read
Investors' Ozempic Mania Could Harm Health Priorities
Metabolic Health

Investors' Ozempic Mania Could Harm Health Priorities

Institutional investors have sidelined climate change in ESG priorities, favoring health tech fueled by Ozempic and GLP-1 drugs. A Berenberg Bank survey of 200 investors ranks health first as climate slips to fifth. Yet, climate change poses severe health threats from heatwaves to vector-borne diseases—why this mania could backfire.

4 min read
Ozempic Isn't a Magic Fix: Semaglutide Risks in India
Metabolic Health

Ozempic Isn't a Magic Fix: Semaglutide Risks in India

Semaglutide injections like Ozempic have arrived in India at low prices, exciting millions with diabetes and rising obesity. But experts like Dr. Gagandeep Singh caution it's no magic fix—weight returns upon stopping, muscle loss is common, and misuse risks malnutrition. Understand the real story behind these GLP-1 weight loss injections.

6 min read
Share this article
  1. Home
  2. Blog
  3. ROOT Brands® Fills GLP-1 Gap with CRUSH™ & SCULPT™ After Ozempic® & Wegovy®
Shotlee Editorial Team — Health Research & Writing
Written by

Shotlee Editorial Team

Health Research & Writing

Shotlee’s guides and articles are researched and written in-house by the Shotlee Editorial Team. We build every page from primary sources — FDA labels, official prescribing information, and peer-reviewed clinical trials — and cite them directly. Our content is educational and is not a substitute for advice from your own healthcare provider.

View all articles by Shotlee Editorial Team
Shotlee LogoShotlee

Your comprehensive health tracking companion. Track, analyze, and optimize your journey with advanced metrics and community support.

Product

  • Medication Trackers
  • Health Guides
  • Calculators
  • Compare Medications
  • Pricing

Resources

  • Health Blog
  • Support Center

Legal

  • Privacy Policy
  • Terms of Service
  • Community Guidelines
  • Refund Policy

© 2026 Shotlee. All rights reserved.

Made with for the community♥ for the community